Skip to main content
Clinical Trials/CTRI/2012/11/003141
CTRI/2012/11/003141RecruitingPhase 2

Assessment of compliance to treatment, disease outcomes, and quality-of-life in patients with poor-prognosis high-grade glioma treated with continuous short-course hypofractionated radiation therapy - SHORT

Tata Memorial Centre Tata Memorial Hospital0 sites55 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
55

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Poor-prognosis HGG defined as
  • a] Patient aged >18 but <=50 years with KPS <=40 and/or NPS>=3
  • b] Patients aged >50 but <=65 years with KPS <=60 and/or NPS >=2
  • c] Patients over >65 years of age with KPS <=80 and/or NPS >=1
  • 2. Histo-pathologically proven HGG including variants 3. Available pre-surgical imaging (CT/MRI)
  • 4. Written informed consent from patient/care- giver
  • 5. Adjuvant therapy starting within 6 weeks (preferably within 4 weeks) of surgery
  • 6. Life-expectancy of at least 3 months

Exclusion Criteria

  • 1 Children 18 years of age
  • 2 Patients deemed suitable for conventionally fractionated radiotherapy
  • 3 Unconfirmed histology
  • 4 Recurrent/progressive disease or
  • transformed HGG from previous low-grade glioma
  • 5 Carmustine wafers implanted at surgery
  • 6 Pregnancy or lactating women

Investigators

Sponsor
Tata Memorial Centre Tata Memorial Hospital

Similar Trials